FLGT
Fulgent Genetics, Inc.
FLGT trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over FLGT overall, supported by stronger fundamentals and lower modeled downside.
FLGT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
FLGT's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
FLGT PE Valuation
FLGT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
FLGT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect FLGT's losses to grow, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over FLGT on the outlook, with more favorable earnings and profitability expectations.
FLGT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.10 | -$1.71 |
| Q2 2026 | -$2.83 | -$1.17 |
| Q1 2026 | -$2.40 | -$1.07 |
| Q4 2025 | -$1.97 | -$0.56 |
| Q3 2025 | -$1.39 | +$4.12 |
| Q2 2025 | -$1.66 | +$3.81 |
| Q1 2025 | -$1.33 | +$4.23 |
| Q4 2024 | -$1.41 | +$4.22 |
FLGT lost $3.10 per share over the past year, and its loss has widened in each of the last four quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over FLGT on earnings quality, reporting a profit while its opponent remains loss making.
FLGT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $90.4M | +7.5% |
| Q2 2026 | $85.4M | +4.4% |
| Q1 2026 | $71.1M | -3.2% |
| Q4 2025 | $83.3M | +9.3% |
| Q3 2025 | $84.1M | +17% |
| Q2 2025 | $81.8M | +15% |
| Q1 2025 | $73.5M | +14% |
| Q4 2024 | $76.2M | +8.1% |
FLGT's revenue is recovering but still below its 2021 peak: $90M last quarter, up 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | -6.7 points |
| Q2 2026 | -42% | -18 points |
| Q1 2026 | -49% | -22 points |
| Q4 2025 | -43% | -22 points |
| Q3 2025 | -18% | +5.5 points |
| Q2 2025 | -24% | +2.5 points |
| Q1 2025 | -27% | +6.8 points |
| Q4 2024 | -21% | +193 points |
FLGT's operating margin was −25% last quarter, down 6.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over FLGT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over FLGT on profitability, with a higher operating margin.
FLGT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $107.4M | +2025% |
| Q2 2026 | -$27.6M | +$9.4M |
| Q1 2026 | $1.9M | +$11M |
| Q4 2025 | -$83.1M | -491% |
| Q3 2025 | $5.1M | +$40.1M |
| Q2 2025 | -$37M | -$28.3M |
| Q1 2025 | -$9.1M | -385% |
| Q4 2024 | $21.2M | +80% |
FLGT's free cash flow was −$1M over the past year, against −$20M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over FLGT on cash generation, producing positive trailing cash flow while its opponent burns cash.
FLGT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -343K shares |
| 1 year | -10% | -3.1M shares |
| 3 years | -7.8% | -2.4M shares |
| 5 years | -11% | -3.5M shares |
| Available history | +48% | +9M shares |
FLGT has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $251,000 |
| Q2 2026 | $23.8M |
| Q1 2026 | $40.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.2M |
| Q1 2025 | $8.7M |
| Q4 2024 | — |
FLGT spent $64M buying back its own shares over the past year, about six times what it spent the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
FLGT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.4x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
| Q2 2022 | -0.2x | Net Cash |
| Q1 2022 | -0.6x | Net Cash |
| Q4 2021 | -0.2x | Net Cash |
| Q3 2021 | -0.3x | Net Cash |
| Q2 2021 | -0.1x | Net Cash |
| Q1 2021 | -0.3x | Net Cash |
FLGT has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
FLGT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 79.5 | Neutral |
FLGT's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
FLGT PE vs Healthcare Sector
| Metric | FLGT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
FLGT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
FLGT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.8 | 14% above |
| 20 week MA | $20.6 | 21% above |
| 50 week MA | $20.5 | 22% above |
| 100 week MA | $20.4 | 22% above |
| 200 week MA | $23.7 | 4.9% above |
FLGT has climbed back above all five of its weekly moving averages, and it's now 4.9% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
FLGT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.2 | $45.8 | +246% |
| 2021 | $45.8 | $100.2 | +119% |
| 2022 | $100.2 | $30.3 | -70% |
| 2023 | $30.3 | $28.9 | -4.7% |
| 2024 | $28.9 | $18.4 | -36% |
| 2025 | $18.4 | $26.7 | +45% |
| 2026 YTD | $26.7 | $24.9 | -7% |
FLGT's yearly returns have swung widely, from +246% in 2020 to −70% in 2022. It's down 7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over FLGT on returns for 2026, with the stronger performance.